We are international
Donate
• IMF TV TEXT SIZE   
webcasts from medical meetings    back

Sundar Jagannath, MD, St. Vincents Comprehensive Cancer Center, New York, NY
06.08.04

Dr. Jagannath discusses first-line therapy with bortezomib (formerly PS-341) {Velcade®} in patients with multiple myeloma (MM).






 related articles
Understanding VELCADE as a Subcutaneous (SQ) Injection
New! Tip Card on Subcutaneous VELCADE
Patients Personifying Progress: Mary Ming-Mosely
Subcutaneous VELCADE® Site
The VELCADE® Website
VELCADE® Downloadable Resources
Randomized Phase III Study Comparing Conventional-Dose Treatment Using a Combination of Lenalidomide (Revlimid®), Bortezomib (Velcade®), and Dexamethasone (RVD) to High-Dose Treatment with Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age
Open Velcade® (bortezomib) Trials
Eastern Cooperative Oncology Group Clinical Trial:E1A05
Understanding VELCADE® (bortezomib) for Injection
VTD Superior to VCD Prior to Intensive Therapy
Study Evaluates Bortezomib Combinations in Frail Myeloma Patients
Addition of bortezomib statistically enhanced the PFS and OS in previously untreated MM
Triple Drug Combination Beats Standard Treatment in Myeloma Trial
Subcutaneous VELCADE® Approved in the EU for the Treatment of Multiple Myeloma
FDA Approves Subcutaneous Administration of VELCADE® In All Approved Indications
VELCADE Reimbursement Assistance Program
Millennium: The Takeda Oncology Company's Web Site
Archived VELCADE Webcasts
News About VELCADE®


You might also be interested in:

General Information
Understanding VELCADE as a Subcutaneous (SQ) Injection
Two short videos explaining what you need to know about VELCADE SQ.

New! Tip Card on Subcutaneous VELCADE

Patients Personifying Progress: Mary Ming-Mosely
Two months ago, I started on VELCADE subcutaneous. It’s just a shot. I don’t have to wait for an IV. It’s just in-and-out. VELCADE has kept me going and feeling well enough to live my life.

Subcutaneous VELCADE® Site
The US Food and Drug Administration (FDA) has approved subcutaneous VELCADE for the treatment of multiple myeloma. This approval was based on a large, international clinical trial that studied VELCADE injected under the skin compared with VELCADE injected into a vein. The 222 patients in this study had been treated for their myeloma and relapsed.

The VELCADE® Website
Information for patients and clinicans on indications and usage.

VELCADE® Downloadable Resources

Clinical Trials
Randomized Phase III Study Comparing Conventional-Dose Treatment Using a Combination of Lenalidomide (Revlimid®), Bortezomib (Velcade®), and Dexamethasone (RVD) to High-Dose Treatment with Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age

This study, sponsored by Dr. Paul Richardson of the Dana-Farber Cancer Institute, was designed to answer a very important question in myeloma: In the era of novel drugs, is high-dose therapy (HDT) still necessary in the initial management of multiple myeloma in younger patients? In this study, the addition of HDT to conventional dose treatment (RVD) as compared to conventional-dose treatment (RVD) alone would be considered superior if it significantly prolongs progression-free survival by at least 9 months.


Open Velcade® (bortezomib) Trials

Eastern Cooperative Oncology Group Clinical Trial:E1A05
Randomized Phase III Trial of Consolidation Therapy with Bortezomib (Velcade®) & Lenalidomide (Revlimid®) - Dexamethasone (VRD) versus Bortezomib (Velcade®:) - Dexamethasone (VD) for Patients With Multiple Myeloma Who Have Completed a Dexamethasone Based Induction Regimen

Publications
Understanding VELCADE® (bortezomib) for Injection
Part of the IMF's Understanding series, this booklet covers the basics, including: What is VELCADE®? How does it work? How is VELCADE® given? How is it used in clinical practice today? What are the side effects?

News
VTD Superior to VCD Prior to Intensive Therapy
Bortezomib plus thalidomide and dexamethasone (VTD) is preferential to bortezomib with cyclophosphamide and dexamethasone (VCD) in preparation of autologous hematopoietic cell transplantation (HCT) for patients with multiple myeloma, a study published in the journal Blood has shown.1

Study Evaluates Bortezomib Combinations in Frail Myeloma Patients
A 2-drug combination with subcutaneous bortezomib and oral prednisone followed by maintenance therapy should be the preferred treatment for frail patients with multiple myeloma, a study published in the journal Leukemia has shown

Addition of bortezomib statistically enhanced the PFS and OS in previously untreated MM

Dr. Brian Durie discussed the randomized phase 3 SWOGG S0777 trial that investigated the addition of bortezomib to lenalidomide and dexamethasone for previously untreated multiple myeloma patients without an intend for immediate autologous stem cell transplant.


Triple Drug Combination Beats Standard Treatment in Myeloma Trial
A SWOG trial shows bortezomib, lenalidomide, and dexamethasone delays recurrence and lengthens life for myeloma patients, indicating a possible new standard of care.

Subcutaneous VELCADE® Approved in the EU for the Treatment of Multiple Myeloma
The approval is based on data from a Phase III study demonstrating that subcutaneous administration of bortezomib is equally effective as intravenous bortezomib but is associated with a significant reduction in the frequency and severity of side effects.

FDA Approves Subcutaneous Administration of VELCADE® In All Approved Indications
Study met primary efficacy endpoint of non-inferiority between subcutaneous and intravenous administration.
Study results also indicated overall similar safety profile with differences in incidence of peripheral neuropathy.

Links
VELCADE Reimbursement Assistance Program
Program is available to patients, physicians, and caregivers to provide assistance regarding reimbursement issues related to the use of VELCADE® (bortezomib) for Injection.

Millennium: The Takeda Oncology Company's Web Site

Archive
Archived VELCADE Webcasts
Webcasts on VELCADE research from past medical meetings.

News About VELCADE®
Past articles and press releases about VELCADE.